+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Abraxane 2018 U.S. Promotional Audit Report

  • ID: 4615820
  • Report
  • Region: United States
  • 29 pages
  • MD Details
1 of 3

FEATURED COMPANIES

The 5 Key Questions Addressed by this Report:
  • How many physicians were reached by Abraxane through reportable promotional activity in 2018 and how does this compare to its peer set in the Breast Cancer, Non-Small Cell Lung Cancer, and Pancreatic Cancer markets?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity?
  • How does Celgene's depth of coverage vary within key specialties (e.g., Hematology/Oncology, Medical Oncology, Internal Medicine, Radiation Oncology, Diagnostic Radiology, and Pathology) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Abraxane throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for Abraxane in 2018?
Data Sources and Methodology:
  • Author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available - covering payments to more than 1,000,000 U.S. healthcare professionals.
  • Over 5,000 paid interactions across 2,500 physicians made on behalf of Abraxane were carefully examined to support our analysis. In addition, interaction data from 31 peer products (i.e. Afinitor, Alecensa, Alimta, Alunbrig, Avastin, Cyramza, Fareston, Faslodex, Gilotrif, Halaven, Herceptin, Ibrance, Imfinzi, Ixempra, Kadcyla, Keytruda, Kisqali, Lorbrena, Lynparza, Nerlynx, Onivyde, Opdivo, Perjeta, Sutent, Tagrisso, Talzenna, Tecentriq, Verzenio, Vizimpro, Xalkori, and Zykadia) was leveraged to provide benchmarking and market insights.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

Overview:
  • Introduction
  • Sunshine Act and Open Payments Data
  • Transfer of Value
  • Author's Platform
Abraxane - Peer Set:
  • Abraxane Peer Set Selection
Abraxane - Promotional Benchmarking:
  • Chart 1 Total Number of Physicians Reached by Specialty Type
  • Chart 2 Distribution of Physicians Reached by Specialty Type
  • Chart 3 Total Number of Payments by Type
  • Chart 4 Distribution of Payments by Type
  • Chart 5 Total Number of Payments / Week
  • Chart 6 Payment Value by Type
Abraxane - Physician Coverage by Geography:
  • Chart 7 Hematology/Oncology
  • Chart 8 Medical Oncology
  • Chart 9 Internal Medicine
  • Chart 10 Radiation Oncology
  • Chart 11 Diagnostic Radiology
  • Chart 12 Pathology
Abraxane - Meal Frequency:
  • Chart 13 Hematology/Oncology
  • Chart 14 Medical Oncology
  • Chart 15 Internal Medicine
  • Chart 16 Radiation Oncology
  • Chart 17 Diagnostic Radiology
  • Chart 18 Pathology
Abraxane - Most Engaged Physicians:
  • Table 1: Top Physicians (By Total Number of Meals) in 2018
  • Table 2: Top Speakers (By Total Number of Speaking Events) in 2018
About:
  • Background
  • Service Lines
  • Contact
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Celgene
Note: Product cover images may vary from those shown
Adroll
adroll